These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34517192)

  • 61. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    Braune S; Lang M; Bergmann A;
    J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
    Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
    Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
    Spelman T; Frisell T; Piehl F; Hillert J
    Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.
    Hua LH; Hersh CM; Tian F; Mowry EM; Fitzgerald KC
    Mult Scler Relat Disord; 2021 Jan; 47():102637. PubMed ID: 33276238
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Disability progression
    von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
    Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characterizing relapsing remitting multiple sclerosis patients burdened with hypertension, hyperlipidemia, and asthma.
    Sorensen A; Conway DS; Briggs FBS
    Mult Scler Relat Disord; 2021 Aug; 53():103040. PubMed ID: 34058603
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.
    Boster AL; Ford CC; Neudorfer O; Gilgun-Sherki Y
    Expert Rev Neurother; 2015 Jun; 15(6):575-86. PubMed ID: 25924547
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
    Jalaleddini K; Bermel RA; Talente B; Weinstein D; Qureshi F; Rasmussen M; Menon S; Amarapala M; Jordan K; Ghoreyshi A; McCurdy S; Edgeworth M
    Mult Scler; 2024 Mar; 30(3):432-442. PubMed ID: 38374525
    [TBL] [Abstract][Full Text] [Related]  

  • 73. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
    Ferraro D; Camera V; Baldi E; Vacchiano V; Curti E; Guareschi A; Malagù S; Montepietra S; Strumia S; Santangelo M; Caniatti L; Foschi M; Lugaresi A; Granella F; Pesci I; Motti L; Neri W; Immovilli P; Montanari E; Vitetta F; Simone AM; Sola P
    Curr Med Res Opin; 2018 Oct; 34(10):1803-1807. PubMed ID: 29526118
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
    Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
    Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
    J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
    Duquette P; Yeung M; Mouallif S; Nakhaipour HR; Haddad P; Schecter R
    PLoS One; 2019; 14(1):e0210417. PubMed ID: 30640935
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk of depression in multiple sclerosis across disease-modifying therapies.
    Longinetti E; Frisell T; Englund S; Reutfors J; Fang F; Piehl F
    Mult Scler; 2022 Apr; 28(4):632-641. PubMed ID: 34264143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.